The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji(Westlake University), Kwok‐Kin Wong(NYU Langone Health), Takeshi Shimamura(University of Illinois Chicago), Robert F. Padera(Brigham and Women's Hospital), Ruqayyah Al-Hashem(Brigham and Women's Hospital), Geoffrey I. Shapiro(Brigham and Women's Hospital), Danan Li(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Bruce E. Johnson(Harvard University), Norman E. Sharpless(University of North Carolina at Chapel Hill), Daniel G. Tenen(Harvard University), Susumu Kobayashi(Beth Israel Deaconess Medical Center), Umar Mahmood(Athinoula A. Martinos Center for Biomedical Imaging), Ralph Weissleder(Massachusetts General Hospital), William Kim(University of San Diego), Lucian R. Chirieac(Mount Sinai Hospital), Liang Chen(Henan Medical University), Mitchell Albert(Brigham and Women's Hospital), Kate McNamara(Dana-Farber/Harvard Cancer Center), Roderick T. Bronson(Harvard University), Yangping Sun(Brigham and Women's Hospital)
Cited by 451
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k